Previous 10 | Next 10 |
JENA, Germany, June 17, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, will present virtually at the Raymond James Human Health Innovation Conference being held Ju...
InflaRx N.V. (IFRX) starts enrollment in the mid-stage trial of its vilobelimab treatment in certain patients with cutaneous squamous cell carcinoma ((cSCC)), the second most common form of skin cancer.The open-label, multicenter Phase II trial is evaluating vilobelimab alone and in...
Proof-of-concept trial will evaluate vilobelimab alone and in combination with pembrolizumab JENA, Germany, June 08, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement...
JENA, Germany, May 21, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced Mr. Tony Gibney has been appointed as a Non-Executive Director to the Board o...
Gainers: Ra Medical Systems (RMED) +67%, Nemaura Medical (NMRD) +23%, Lucira Health (LHDX) +21%, Minerva Neurosciences (NERV) +20%, Harrow Health (HROW) +19%.Losers: InflaRx (IFRX) -15%, Praxis Precision Medicines (PRAX) -14%, Lianlu...
Severe COVID-19 trial enrollment reaches 178 patients; interim analysis expected in Q3 At the FDA’s suggestion, planning to request a Type A meeting to further discuss primary endpoint for the Phase III clinical development of vilobelimab in Hidradenitis Suppurativa Vil...
InflaRx (IFRX) says that the company reached the primary objective in a Phase II study with vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody ((ANCA))-associated vasculitis or AAV.The randomized, double-blind, placebo-controlled study conducted in the U.S. invol...
U.S. IXPLORE Phase II trial achieved its objective; vilobelimab was shown to be safe and well tolerated in patients with ANCA-associated vasculitis when added to current standard of care EU IXCHANGE Phase II trial is fully enrolled with results expected by the end of 2021 JENA, ...
InflaRx N.V. (IFRX) announces the achievement of target enrollment of the Phase IIa open label study of vilobelimab in patients with Pyoderma Gangraenosum ((PG)), a rare and debilitating neutrophil-driven, autoinflammatory skin disease.The open-label Phase IIa proof-of-concept study...
Submitted a Special Protocol Assessment to the FDA for Phase III program evaluating vilobelimab in Hidradenitis Suppurativa (HS) in Q1 2021 Phase III trial in Severe COVID-19 is ongoing and recruiting patients Topline data from Phase II US trial in ANCA-Associated Vasculitis expec...
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...